Abstract
Identification of genes and pathways that alter lifespan has allowed for new insights into factors that control the aging process as well as disease. While strong molecular links exist between aging and metabolism, we hypothesize that targeting the mechanisms involved in aging will also give rise to therapeutics that treat other devastating age-related diseases, such as neurodegeneration, cancer, inflammation and cardiovascular disease. Insulin sensitivity, glycemic control and adiposity are not only hallmarks of the major metabolic diseases, type 2 diabetes and obesity, but they also represent significant risk factors for the development of Alzheimers Disease and cognitive impairment. Insulin/IGF-1 signaling is an important pathway regulating aging and disease in a variety of species, including mammals. Here we describe an important role for the gut-derived peptide ghrelin in upstream signaling through the insulin/IGF-1 pathway and exemplify modulation of ghrelin signaling as an approach to mechanistic treatment of multiple age-related diseases by virtue of its ability to regulate key metabolic functions.
Keywords: IGF-1 receptor, Ghrelin, GHSR-1a knockouts, advanced glycation end products, Alzheimer Disease
Current Alzheimer Research
Title: Insulin Resistance, Glycemic Control and Adiposity: Key Determinants of Healthy Lifespan
Volume: 4 Issue: 2
Author(s): Peter S. DiStefano, Rory Curtis and Bradley J. Geddes
Affiliation:
Keywords: IGF-1 receptor, Ghrelin, GHSR-1a knockouts, advanced glycation end products, Alzheimer Disease
Abstract: Identification of genes and pathways that alter lifespan has allowed for new insights into factors that control the aging process as well as disease. While strong molecular links exist between aging and metabolism, we hypothesize that targeting the mechanisms involved in aging will also give rise to therapeutics that treat other devastating age-related diseases, such as neurodegeneration, cancer, inflammation and cardiovascular disease. Insulin sensitivity, glycemic control and adiposity are not only hallmarks of the major metabolic diseases, type 2 diabetes and obesity, but they also represent significant risk factors for the development of Alzheimers Disease and cognitive impairment. Insulin/IGF-1 signaling is an important pathway regulating aging and disease in a variety of species, including mammals. Here we describe an important role for the gut-derived peptide ghrelin in upstream signaling through the insulin/IGF-1 pathway and exemplify modulation of ghrelin signaling as an approach to mechanistic treatment of multiple age-related diseases by virtue of its ability to regulate key metabolic functions.
Export Options
About this article
Cite this article as:
DiStefano S. Peter, Curtis Rory and Geddes J. Bradley, Insulin Resistance, Glycemic Control and Adiposity: Key Determinants of Healthy Lifespan, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362038
DOI https://dx.doi.org/10.2174/156720507780362038 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Postoperative Delirium
Current Drug Targets Onset Age and Clinical Heterogeneity of Dementias: A Diagnostic and Therapeutic Approach
Current Psychopharmacology Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
CNS & Neurological Disorders - Drug Targets Disrupted White Matter Networks from Subjective Memory Impairment to Amnestic Mild Cognitive Impairment
Current Alzheimer Research Host Neuro- Immuno-Endocrine Responses In Periodontal Disease
Current Pharmaceutical Design Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Current Drug Targets Is Age of 80 Years a Threshold for Carotid Revascularization?
Current Cardiology Reviews Electroconvulsive Therapy for Schizophrenia
Current Psychiatry Reviews Cerebral Amyloid Angiopathy: A Common Cause of Cerebral Hemorrhage
Current Medicinal Chemistry Anti-VEGF Molecules for the Management of Diabetic Macular Edema
Current Pharmaceutical Design Influence of Impaired Liver Methionine Metabolism on the Development of Vascular Disease and Inflammation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Ageing Mechanisms and Associated Lipid Changes
Current Vascular Pharmacology Novelty in Inflammation and Immunomodulation in Migraine
Current Pharmaceutical Design Targeting RGD Recognizing Integrins: Drug Development, Biomaterial Research, Tumor Imaging and Targeting
Current Pharmaceutical Design Regulatory Cascade of Neuronal Loss and Glucose Metabolism
CNS & Neurological Disorders - Drug Targets Editorial [Celebrating the Fifth Year Anniversary of Current Alzheimer Research(Guest Editor: Debomoy K. Lahiri)]
Current Alzheimer Research Inflammatory Biomarkers in AD: Implications for Diagnosis
Current Alzheimer Research Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy
CNS & Neurological Disorders - Drug Targets Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry The Pathophysiology of Heme in the Brain
Current Alzheimer Research